← All trials
NCT05999240
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2023
- Primary completion
- Oct 15, 2025
- Completion date
- Dec 15, 2025
- First posted
- Aug 21, 2023
- Last posted
- Nov 8, 2023
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Columbia UniversityLead sponsor
- Acadia PharmaceuticalsCollaborator
- Columbia UniversityOverall official - principal investigator
- Columbia UniversityReponsible party - principal investigator
- Research Foundation for Mental Hygiene, Inc.Collaborator
- University of KansasCollaborator
- Cornell UniversityCollaborator
- Columbia UniversityOfficial
- Columbia UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.